Insights Into the Emerging Entity of HER2-Low Breast Cancer

Insights Into the Emerging Entity of HER2-Low Breast Cancer

Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other m...

Full description

Saved in:

Bibliographic Details
Main Authors:	Georges El Haddad, Ernest Diab, Michel Hajjar, Maroun Aoun, Farid Mallat, Ziad Zalaquett, Hampig-Raphael Kourie
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	International Journal of Breast Cancer
Online Access:	http://dx.doi.org/10.1155/2024/2853007
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Vulvar Metastasis from Bladder Cancer
by: Fouad Aoun, et al.
Published: (2015-01-01)

Epidemiology of bone tumors in Lebanon: a retrospective study from 2000 to 2022 at a tertiary center
by: Mohammad Daher, et al.
Published: (2023-10-01)

Podocyturia an emerging biomarker for kidney injury
by: Charbel Hanna, et al.
Published: (2025-03-01)

Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon
by: Roland Eid, et al.
Published: (2020-06-01)

Emergence of a new me: Experiences of women diagnosed with HER2-positive breast cancer
by: Josianne Scerri, et al.
Published: (2025-01-01)

Emergence of a new me: Experiences of women diagnosed with HER2-positive breast cancer.
by: Josianne Scerri, et al.
Published: (2025-01-01)

Pachychoroid Spectrum - An Emerging Clinical Entity
by: Prof. (Dr.) Kumar Atul, et al.
Published: (2019-07-01)

Caveolin-1: an ambiguous entity in breast cancer
by: Naveen Chintalaramulu, et al.
Published: (2025-04-01)

Chagas disease: an emerging food-borne entity?
by: Alfonso J. Rodriguez-Morales
Published: (2008-04-01)

Biodiversity reporting: Comparing listed entities in the United Kingdom and South Africa
by: Dino Da Mata, et al.
Published: (2025-01-01)

HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd
by: Christian Fridolin Singer, et al.
Published: (2025-04-01)

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Å telle etniske minoriteter: Helgøy herred 1900 til 1920
by: Georges Midré
Published: (2024-06-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status
by: Chihwan David Cha, et al.
Published: (2025-03-01)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
by: Samar M Alanazi, et al.
Published: (2023-01-01)

Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01)

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
by: Gokce Deniz Ardor, et al.
Published: (2023-01-01)

Breast relapse after metastatic alveolar rhabdomyosarcoma: Is it an incurable entity?
by: Silvia López Iniesta, et al.
Published: (2016-01-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Present and future of breast cancer anti-Her-2-therapy
by: V. P. Letyagin
Published: (2014-07-01)

POSSIBILITIES OF THERAPY OF HER-2-POSITIVE REGIONAL BREAST CANCER
by: A. S. Belokhvostova, et al.
Published: (2015-04-01)

Small HER2 positive breast cancer: When is enough?
by: Randeep Singh, et al.
Published: (2018-01-01)

IN SILICO STUDY: THE POTENTIAL OF KILEMO (Litsea cubeba) ENDEMIC PLANT FROM KALIMANTAN AS ANTI-BREAST CANCER THROUGH HER2 INHIBITION
by: Dwi Utami, et al.
Published: (2025-03-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
by: Qiuyan Yu, et al.
Published: (2015-01-01)

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
by: Karam Aboud, et al.
Published: (2025-07-01)

Correction: HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
by: PLOS ONE Staff
Published: (2024-01-01)

PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
by: Xin Zhao, et al.
Published: (2025-04-01)

Experience with Renal Autotransplantation: Typical and Atypical Indications
by: Ali Bourgi, et al.
Published: (2018-01-01)

Urological outcomes and management of abnormal placental presentations: a retrospective study at a Lebanese center
by: Georges Yared, et al.
Published: (2025-12-01)

Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
by: Manlu Cui, et al.
Published: (2024-10-01)

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer
by: Xi Li, et al.
Published: (2025-03-01)

Reading scripture through a mystical lens
by: Celia Kourie
Published: (2011-06-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
by: Lennart Hohmann, et al.
Published: (2025-03-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-08-01)

Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups
by: Erkan Ozcan, et al.
Published: (2025-01-01)